—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Ascendis Pharma AS (ASND) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ASND, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 71, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-09
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 96th percentile of the window, +4.3% over 20 sessions. Factor regime → 2026-10-09
  • Sector × region Health care in US: +2.8% week · +3.5% month · +6.2% quarter · +17.8% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-11
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09
How it trades on rate days beta 0.46 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How ASND has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.46 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Ascendis Pharma AS moved 0.46% on average · correlation 0.11 · higher than 45% of US names
  • Beta, last 3 months 0.59 about the same as over the year
  • On the 10 worst bond days −0.66% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +3.39% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ASND on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Ascendis Pharma AS

ASND in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Ascendis Pharma builds drugs on its TransCon platform, which controls how a molecule releases in the body over time. It sells Skytrofa for children with growth hormone deficiency and Yorvipath for adults with chronic hypoparathyroidism. Its pipeline extends into other rare endocrine conditions and oncology. The company is based in Hellerup, Denmark, and lists in the United States.
Where it sits in the stack
Ascendis Pharma sits in our Healthcare sleeve, grouped with other Healthcare names listed in the United States; it plays no part in the AI build-out stack the diary tracks through our index.
Who it is priced against
Closelooknet's peer group places it with other scored Healthcare names domiciled and listed in the United States, including argenx, Regeneron and Vertex Pharmaceuticals; the market also compares it with Novo Nordisk on the endocrine side.
Why Closelooknet tracks it
It carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest. It holds no seat in our index and has drawn no quotes in the diary so far.
What the diary watches
Whether the endocrinology pipeline delivers further approvals and how the gap between its share price and the trimmed analyst target closes or widens.

Ascendis Pharma AS (ASND) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 50/100 composite (momentum 39, quality 63, valuation 30) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 7 analyst actions on the wire · latest: price target by Oppenheimer, 2026-09-01

The Street on this name

Analyst actions and the latest print for ASND from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Oppenheimer — target 312 Target set to $312 (+19.9% to spot) 2026-09-01
  • Price target Morgan Stanley — target 273 from 275 Target cut to $273 from $275 (+3.8% to spot) 2026-09-01
  • Price target Jefferies — target 330 from 333 Target cut to $330 from $333 (+24.4% to spot) 2026-08-31

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 17 m USD in FY2025

Dividends and capital return

What ASND pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 17 m USD 0.1% of today's market value
  • Share count +4.7% in FY2025 116 m USD of stock-based compensation in the year
  • Capital returned 17 m USD · 38% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-10

Quick answers

What is Ascendis Pharma AS (ASND)?

Ascendis Pharma AS trades as ASND on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-10.

Is ASND in a Closelooknet index?

Not currently — Ascendis Pharma AS is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-10.

What is Ascendis Pharma AS's Closelooknet composite score?

50 out of 100, with momentum 39, quality 63 and valuation 30 sub-scores, as of 2026-10-10. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ASND trade against its moving averages?

Mixed moving-average stack: Trades -6.9% vs the 50-day and -2.9% vs the 200-day average, 18.8% below the 52-week high and +23.2% off the 52-week low. Computed from daily closes. As of 2026-10-09 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Ascendis Pharma AS compare with its peers?

Against its peer group (Biotechnology · US), Ascendis Pharma AS (ASND) sits 18.8% below its 52-week high, 6.9% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 5.5% below, BeiGene, Ltd. (ONC) is 8.0% below, argenx NV ADR (ARGX) is 23.1% below. Put any of them next to ASND in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Ascendis Pharma AS trade when bond yields rise?

Over the past year Ascendis Pharma AS had a beta of 0.46 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 45% of US names. On the 10 sessions in which long bonds fell most it moved −0.66% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Ascendis Pharma AS do?

Ascendis Pharma builds drugs on its TransCon platform, which controls how a molecule releases in the body over time. It sells Skytrofa for children with growth hormone deficiency and Yorvipath for adults with chronic hypoparathyroidism. Its pipeline extends into other rare endocrine conditions and oncology. Closelooknet's peer group places it with other scored Healthcare names domiciled and listed in the United States, including argenx, Regeneron and Vertex Pharmaceuticals; the market also compares it with Novo Nordisk on the endocrine side.

Where does Ascendis Pharma AS sit in the AI build-out?

Ascendis Pharma sits in our Healthcare sleeve, grouped with other Healthcare names listed in the United States; it plays no part in the AI build-out stack the diary tracks through our index. It carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest. It holds no seat in our index and has drawn no quotes in the diary so far.

Does Ascendis Pharma AS pay a dividend?

No cash distribution shows in Ascendis Pharma AS’s price series over the last three years. In fiscal 2025 the company bought back 17 m USD of its own shares, 38% of that year’s free cash flow. The share count rose 4.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Ascendis Pharma AS recently?

The most recent analyst action on Ascendis Pharma AS on the Closelooknet wire is a price target by Oppenheimer on 2026-09-01 (target 312). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ASND, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.